6 курс / Гастроэнтерология / Особенности_течения_язвенной_болезни_у_работников_производства_соединений

181

375.Югай, Н. В. Оценка качества жизни при артериальной гипертензии на фоне желчнокаменной болезни / Н. В. Югай // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. – 2010. – Т. ХХ, № 1, Прил № 35. – C. 427.

376.Ющук, Н. Д. Иммунный ответ при инфекции, вызванной Helicobacter pylori / Н. Д. Ющук, И. В. Маев, К. Г. Гуревич // Журн. микробиологии. – 2003. – №. 6. – С. 86-91.

377.Язвенная болезнь желудка и двенадцатиперстной кишки: морфофункциональные, нейроэндокринные и клинические параллели / С. И. Раппопорт, Н. И. Жернакова, К. И. Прощаев и др. // Клин. медицина. – 2008. – № 5. – С. 28-30.

378.Язвенная болезнь и хронический гастрит, ассоциированный с инфекцией H.Pylori: дыхательная лазерная диагностика и современная терапия / В. Т. Ивашкин, Е. К. Баранская, Е. В. Степанов и др. // Врач. – 2008. – № 9. – С. 5-11.

379.Abbas, A. K. Functional diversity of helper T Lymphocytes // A. K. Abbas, K.

M.Murphy, А. Sher // Nature. – 1996. – № 383. – Р. 787-793.

380.Advenrse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis / A. C. Ford, P. Malfertheiner, M. Giguere et al. // Word J. Gastroenterol. – 2008. – Vol. 14. – Р. 7361-7370.

381.Akiyama, J. Intestinal metaplasia subtype and gastric cancer risk / J. Akiyama,

N.Uemura // J. Gastroenterol. Hepatol. – 2009. – Vol. 24, № 1. – Р. 4-6.

382.Albeldawi, M. Managing acute upper GI Bleeding, preventing recurrences /

M.Albeldawi, M. A. Qadeer, J. J. Vargo // Cleve. Clin. J. Med. – 2010. – Vol. 77, №. 2. –

P.131-142.

383.Amieva, M. R. Host-bacterial interactions in Helicobacter pylori infection / M.

R.Amieva, E. M. El-Omar // Gastroenterology. – 2008. – Vol. 134, № 1. – Р. 306-323.

384.Anti-Helicobacter pylori immunoglobulin G (IgG) and antibody responses and the value of clinical presentations in diagnosis of H. Pylori infection in patients with precancerous lesions / Li Shao, Lu Ai-Ping, Zhang Lian et al. // World J. Gastroenterol. – 2003.

– Vol. 9, № 4. – Р. 755-758.

385.A population-based study of the drug interaction between proton pump inhibitors and clopidogrel / D. Jurlink, T. Gomes, D. Ko et al. // CMAJ. – 2009. – Vol. 180, № 7.

– Р. 713-8.

386.A proteomic approach for the identification of bismuth-binding proteins in Helicobacter pylori / R. Ge, X. Sun, Q. Gu et al. // J. Bion. Inorg. Chem. – 2007. – Vol. 12.

– P. 831-842.

387.Assessment of the toll-like receptor 4 Asp299Gly, Thr399ile and interleukin- 8-251 polymorfisms in the risk for the development of distal gastric cancer / E. GarzaGonzalez, F. J. Bosgues-Padilla, S. L. Mendozalbarra et al. // BMC Cancer. – 2007. – Vol.

26, №. 7. – Р. 70.

388.Association of interleukn-1 gene family polymorphism’s with duodenal ulcer disease / М. А. Garcia-Gonzales, А. Lanas, Р. Н. Savelkoul et al. // Clin. Exp. Mmunol. – 2003. – Vol. 134, № 3. – Р. 525-531.

389.Association of H. Pylori cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases /

E.Kamali-Sarvestani, A. Bazargani, M. Masoudian et al. // World J. Gastroenterol. – 2006.

– Vol. 12, № 32. – Р. 5205-5210.

182

390.Association of polymorphism’s of interleukn-1 beta gene and Helicobacter pylori infection with the risk of gastric ulcer / Y. T. Chang, M. S. Wu, С. Т. Shun et al. // Hepatogastroenterology. – 2002. – Vol. 49, № 47. – Р. 1474-1476.

391.Atberton, J. C. The patogenesis of Helicobacter pylori-induced gastroduodenal diseases / J. C. Atberton // Ann. Rev. Patbol. – 2006. – № 1. – Р. 63-96.

392.Basophils infiltrate human gastric mucosa at sites of Helicobacter pylori infection, and exhibit hemotaxis in response to Helicobacter pylori-derived peptide Helicobacter pylori (2-20) / A. De Paulis, N. Prevete, I. Fiorentino et al. // Immunol. – 2004. – Vol. 172,

№12. – Р. 7734-7743.

393.Cell proliferation and inflammation on biopsy samles with multifocal atrophic gastritis before and 1 year after Helicobacter pylori eradication / J. Guarner, J. Bartlett, R. Seitz et al // Arch. Pathol. Lab. Med. – 2005. – Vol. 129, № 11. – Р. 1451-1456.

394.Challenge model for Helicobacter pylori infection in human volunteers / D. Y. Graham, A. R. Opekun, M. S. Osato et al. // Gut. – 2004. – Vol. 53. – P. 1235-1243.

395.Changes in the localization of perforated peptic ulcer and its relation to gender and age of the patients thoughout the last 45 years / A. Wysocki, P. Budzynski, J. Kulawik, W. Drozdz // World J. Surg. – 2011. – Vol. 35, № 4. – P. 811-6.

396.Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease / S. Y. Bang, D. S. Han, C. S. Eun et al. // Korean J. Gastroenterol.

– 2007. – Vol. 50. – P. 356-362.

397.Cheung, F. K. Management of massive peptic ulcer bleeding / F. K. Cheung, J. Y. Lau // Gastroenterol. Clin. North. Am. – 2009. – Vol. 38, № 2. – P. 231-243.

398.Chey W. D. American College of Gastroenterology Guideline on the management of Helicobacter pylori infection / W. D. Chey, B. C. Wong // Am. J. Gastroenterol.

– 2007. – Vol. 102. – P. 1808-1825.

399.Chronic atrophic antral gastritis and risk of metaplasia and dysplasia in an area with low prevalence of Helicobacter pylori / L. Y. Yeh, M. Raj, S. Hassan et al. // Indian J. Gastroenterol. – 2009. - Vol. 28, № 2. – Р. 49-52.

400.Circulating T-cell response to Helicobacter infection in chronic gastritis / Z. Ren, G. Pang, R. Lee et al. // Helicobacter. – 2000. – № 5. – Р. 135-141.

401.Clarithromicyn resistance and Helicobacter pylori genotypes in Italy / V. De Francesco, M. Margiotta, A. Zulla et al. // J. Microbiol. – 2006. – Vol. 28. – P. 6-13.

402.Clonal analysis of gastric carcinoma and precancerous lesions and its relation to Ki-67 protein expression / L. Wang, L. Zheng, S. Y. Wang et al. // Neoplasma. – 2009. –

Vol. 56, № 1. – Р. 48-55.

403.Comparison between in vivo and in vitro chemokine productions in Helicobacter pylori infection / М. Oshuga, К. Kusugami, К. Ina еt al. // Aliment Pharmacol. Ther.

– 2000. – № 14 (suppl. 1). – Р. 205-215.

404.Correa, P. Carcinogenesis of Helicobacter pylori / P. Correa, J. Houghton // Gastroenterology. – 2007. – Vol. 133. – P. 659-672.

405.Correa, P. The Biological model of gastric carcinogenesis / P. Correa // IARC Sci. Publ. – 2004. – Vol. 157. – P. 301-310.

406.Correlation between serum pepsinogen levels and gastric mucosal gistological findings before and after Helicobacter pylori eradication therapy / Т. Kawai, К. Kawakami, Т. Kudo еt al. // Dig. Endosc. – 2004. – № 16. – Р. 122 – 128.

183

407.Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report / Р. Malfertbeiner, F. Megraud, С. O”Morain et al. // Gut. – 2007. – № 56. – Р. 772-781.

408.Cytokine expressions and H. pylori-associated gastric mucosal lesion / А. Takagi, R. Deguchi, К. Kobayashi, Т. Mwa // Keio J. Med. – 2002. – Vol. 51, № 2. – Р. 51-52.

409.Dairy, calcium and vitamin D intakes and duodenal ulcer risk in the National Health and Nutrition Examination epidemiologic follow-up study cohort / M. Tsend, R. A. Breslow, B. I. Graubard et al. // Am. J. of Clinical Nutrition. – 2005. – Vol. 81, №. 5. – P. 1147-1154.

410.Diagnosis of atrophic gastritis based upon a combination of three non-invasive tests: Preliminary results of the Loiano-Monghidoro project / G. Nicolini, R. Zagari, Р. Pozzato et al. // G. Gastroenterol Hepatol. – 2002. – Vol. 17, № 1. – Р. 264.

411.Diagnosis of atrophic gastritis from serum sample / Р. Sipponen, М. Harkanen, А. Alanko, О. Suovaniemi // Clin. Lab. – 2002. – № 48. – Р. 505-515.

412.Di-er junyi daxue xuebao / Cao Xiao-end, Li Zhaoshen, Zhan Xian-bao et al. // Acad. J. Second. Mil. Med. Univ. – 2006. – Vol. 27, № 8. – P. 863-866.

413.Dockray, G. J. Gastrin. Best Pract / G. J. Dockray // Res. Clin. Endocrinol. Metab. – 2004. – № 18. – Р. 555-568.

414.Effect of Helicobacter pylori eradication on gastric acid secretion and mealstimulated serum gastrin in children / S. Kato, К. Ozawa, Т. Koike et al. // Helicobacter. – 2004. – № 9. – Р. 100 -105.

415.Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer healing and prevention of relapse in gastric ulcer patients / Z. Tulassay, M. Stolte, M. Sjolundc et al. // Eu.r Gastroenterol. Hepatol. – 2008. – Vol. 20. – P. 526-36.

416.Eficacy of one-day guadruple therapy for H. pylori infection in Chinese patients / X. H. Huo, J. K. Chu, X. F. Yang et al. // World journal of gastroenterology. – 2006.

–Vol. 12, № 19. – Р. 3105-3107.

417.El-Omar, E. M. Mechanisms of increased acid secretion after eradication of Helicobacter pylori infection / E. M. El-Omar // Gut. – 2006. – Vol. 55. – P. 144-146.

418.El-Omar, E. M. The importance of interleukin 1b in Helicobacter pylori assocated disease / E.M. El-Omar // Gut. – 2001. – № 48. – Р. 743-747.

419.El-Zimaity, H. Gastritis and Gastric Atrophy / H. El-Zimaity // Curr Opin Gastroenterol. – 2008. – Vol. 24 – Р. 682-86.

420.Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients / J. P. Gisbert, J. L. Gisbert, S. Marcos et al // Alimantory pharmacology and therapeutics. – 2008. – Vol. 27, № 4. – Р. 346-354.

421.Emst, P. B. The disease spectrum of Helicobacter pylori: The immunopathogenesis of gastroduodenal ulcer and gastric cancer / P. B. Emst, D. Gold Benjamin // Annual Review of Microbiology. – 2000. – Vol. 54. – P. 615-640.

422.Eradication rates of Helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease / S. J. Chung, D. H. Lee, N. Kim et al. // Hepato-gastroenterology. – 2007. – Vol. 54, № 76. – Р. 1293-1296.

423.Esomeprazole. A Review of its Use in Management of Gastric Acid-related Diseases in Adults / K. McKeage, S Blick, J. D. Croxtall et al. // Drugs. – 2008. – Vol. 68, № 11. – Р. 1571-607.

184

424.Factors influencing gastric ulcer healingin Helicobacter pylori-positive patients / Z. Tulassy, P. Nagy, M. Gottlow et al. // Gut. – 2008. – Vol. 20. – P. 526-36.

425.Fischbach, L., Evans E. L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori / L. Fischbach, E. L. Evans // Alimant Pharmacol Ther. – 2007. – Vol. 26, № 3. – P. 343-57.

426.Fock, K. M. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer / K. M. Fock, N. J. Talley, P. Moayyedi // Am. J. Gastroenterol. – 2008.

–Vol. 103. – P. 510-4.

427.Functional gastroduodenal disorders / J. Tack, N. J. Talley, M. Camilleri et al // Gastroenterology. – 2006. – Vol. 130. – P. 1466-1479.

428.Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading / М. Rugge, Р. Correa, М. F. Dixon еt al. // Aliment. Pharmacol. Ther. – 2002. – Vol. 16. – P. 1-12.

429.Gastrin biosynthesis in camine G cells / V. Stepa, K. Sugana, Т. Yamada et al. // Amer. J. Physiol. Gastrointest. Liver Physiol. – 2002. – Vol. 282. – P. 766-775.

430.Goto, T. Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice / T. Goto // Infect. Immun. – 1999. – Vol. 67, № 5. – P. 2531-2539.

431.Hatakeyama, M. Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA / M. Hatakeyama // Oncogene. – 2008. – Vol. 27, № 55. – P. 7047-7054.

432.Helicobacter pylory cag pathogenicity island is associated with enhanced in- terleukin-8 expression in human gastric mucosa / В. Orsini, G. Ciancio, S. Cencini et al. // Dig. Liver. Dis. – 2000. – Vol. 32, № 6. – Р. 458-467.

433.Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis / М. Ito, К. Haruma, Т. Kamada et al. // Aliment. Pharmacol. Ther. – 2002. – № 16. – Р. 14449-1456.

434.Helicobacter pylori induces human dendritic cell maturation and duodenal ulcer promoting gene a (dupA) enhances dendritic cell cytokine expression / M. Z. Cader, C. Marx, E. Staples et al. // Gut. – 2011. – Vol. 60. – P. 54.

435.Helicobacter pylori phase variation, immune modulation and gastric autoimmunity / M. Bergman, Del Prete Gianfranco, Kooyk Yvette van et al. // Nature Reviews Microbiology. – 2006. – № 4. – Р. 151-159.

436.Hofner, P. Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with Helicobacter pylori-induced duodenal ulcer and gastritis / P. Hofner, Z. Guulai, Z. F. Kiss // Helicobacter. – 2007. – Vol. 12, № 2. – Р. 124-131.

437.Hypocalcemia and hypomagnesemia due to occupational dermal contract with hydrofluoric acid / P. Garrido, S. Nogue, P. Munne et al. // J. Tоxicol. Clin. Toxicol. – 2001.

–Vol. 39, № 3. – Р. 291.

438.Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter positive and negative gastritis / R. Kartunner, Т. Kartunner, H.P. Ekre еt al. // Gut. – 1995. – № 36. – Р. 341-345.

439.Interleukn-1 beta polymorphism’s increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer reccurrence in Japan / T. Furuta, Е. М. El-Omar, F. Xiao et al. // Gastroenterology. – 2002. – Vol. 123, № 1. – Р. 92-105.

185

440.Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan / A. Taguchi, N. Ohmiya N, K. Shirai et al. // Cancer Epidemiol. Biomarkers Pley. – 2005. – Vol. 14, № 11. – Р. 2487-2493.

441.Involvement of mast cells in gastritis caused by Helicobacter pylori a potential role in epithelial cell apoptosis / V. Hofman, S. Lassalle, E. Selva et al. // Clin. Pathol. – 2007. – Vol. 60, № 6. – P. 600-607.

442.Jafri, N. S. Meta-analysis: seguential therapy appears superior to standart therapy for Helicobacter pylori infection in pations naïve to treatment // N. S. Jafri, C. A.

Hornung, C. W. Howden // Ann. Intern. Med. – 2008. – Vol. 19, № 4. – Р. 243-248.

443.Kay, A. W. Effect of large doses of histamine of gastric secretion of HCL (An angmented histamine test) / A. W. Kay // Brit. Med. J. – 1953. – Vol. 48, № 2. – P. 77-80.

444.Kim, H. Inhibition of lipid peroxidation. NF-kappa И activation and IL-8 production by rebamipide Helicobacter pylori-stimulated gastric epithelial cells / Н. Kim, J. Y. Seo, К. Н. Kim // Dig. Dis. Sci. – 2000. – № 45. – Р. 621-628.

445.Knutsson, A. Health disorders of shft works / А. Knutsson // Occup. Med. (Oxford). – 2003. – Vol. 53, № 2. – P. 103-108.

446.Larsson, S. Milk and lactose intakes and duodenal ulcer risk in Swedish Gastroscophy / S. Larsson, L. Bergkvisk, A. Work // Cohort. Ameri. J. of Nutrition. – 2004.

–Vol. 80. – P. 1353-1357.

447.Lembo, A. Helicobacter pylori infection, immune response and vaccination / A. Lembo, L. Laine, R. Hopkins // Curr. Drug Targets Immune. Endocor. Metabol. Disord.

–2001. – Vol. 1, № 3. – P. 199-208.

448.Livingston, M. Chemokine. Wegmeiser des Immunsystems / M. Livingston // Uni. Press. – 2000. – P. 13-15.

449.Lohoff, M. Helicobacter pylory gastritis: a Th1 mediated disease? / М. Lohoff, М. Rolinghoff , А. Sommer // J. Biotechnology. – 2000. – № 83. – Р. 33-36.

450.Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria / К. Lifima, Н. Sekine, Т. Koike еt al. // Alimet. Pharmacol. Ther. – 2004. – № 19. – Р. 1181-1188.

451.Macola, D. Helicobacter pylori infection and related gastrointestinal diseases / D. Macola, D. A. Peura, S. E. Crowe // J. Clin. Gastroenterol. – 2007. – № 41. – Р. 548-58.

452.Marshall, B. J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis / B. J. Marshall, J. R. Warren // Lancet. – 1983. – Vol. 1, P. 1273-1275.

453.McColl, K. E. L. The role of gastrin in ulcer pathogenesis. Baillieres Best Pract / К. Е. L. McColl, D. Gillen, E. El-Omar // Res. Clin. Gastroenterol. – 2000. – № 14. – Р. 13-26.

454.Megraud, F. Helicobacter pylori detection and antimicrobial susceptibility

testing / F. Megraud, P. Lehours // Clin. Microbiol. Rev. – 2007. –

№20. – Р. 280-322.

455.Modeling the inhibition of human MARK2 kinase by H. pilory Cag A virulence factor / G. Farley, J. Issroff, R. Kaplan et al. // Infect. Immun. – 2011. – Vol. 79. – P. 879-886.

456.Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis / G. Bjelacovic, D. Nicolova, L. L. Gluud et al. // JAMA. – 2007. – Vol. 297. – P. 642-57.

186

457.Mutations in Helicobacter pylori porD and oorDgenes may contribute to furazolidone resistance / Z. Su, H. Xu, C. Zhang et al. // Croat Medical. – 2006. – Vol. 47. – P. 410-5.

458.Nakayama, Y. Helicobacter pylori infection: diagnosis and treatment / Y. Nakayama, D. Y. Graham // Expert Rev Anti-infect Ther. – 2004. – Vol. 2. – P. 599-610.

459.Non-Endoscopic Diagnosis of Atrofic Gastritis with a Blood Test. Correlation between Gastric Histology and Serum Levels of Gastrin-17 and Pepsinogen- I. A Multicenter Study / Н. Vaananen, М. Vauhkonen, Т. Helske et al. // Eur Gastroenterol Hepatol. – 2003. – № 15. – Р. 885-891.

460.Novel probiotic bifidobacterium bifidum CECT 7366 strain actuve against the pathogenic bacterium Helicobacter pylori / E. Chenoll, B. Casinos, E. Bataller et al. // Appl.

Envir. Microbiol. – 2011. Vol. 77. P. 1335-1343.

461.OLGA staging for gastritis: a tutorial / M. Rugge, P. Correa, Di Mario et al. // Dig Liver Dis. – 2008. – Vol. 40, № 8. – P. 650-8.

462.Patients with Helicobacter pylori positive and negative duodenal ulcers have distinct characteristics / K. M. Chu, K. F. Kwok, S. Law et al. // World J. Gastroenterol. – 2005. – Vol. 11, №. 23. – P. 3518-3522.

463.Phenotype analysis of lymphocytes of workers with chronic benzene poisoning / M. M. Brandao, M. A. V. Rego, L. Pugliense et al. // Immunol. Lett. – 2005. – Vol.

101, № 1. – Р. 65-67.

464.Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland) / F. Kamangar, C. C. Abnet, A. A. Hutchinson et al. // Cancer Causes Control. – 2006.

–Vol. 176, № 1. – Р. 117-125.

465.Prevalence of peptic ulcer in dyspeptic patients and the influence of age, sex and Helicobacter pylori infection / Wu Hui-Chao, Tuo bi-Guang, Wu Wei-Min et al. // Diseases and Scr. – 2008. – Vol. 53, № 10. – P. 2650-2656.

466.Proinflammatory cytokine gene expression in the stomach correlates with vac- cine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase / C. F. Flach, A. K. Ostberg, A. T. Nilsson et al. // Infect. Immun. – 2011. – Vol. 79. – P. 879-886.

467.Rad, R. Cytokine gene polymorphisms influence mucosal cytokine exspression, gastric inflammation, and host specific colonization during Helicobacter pylori infection / R. Rad, A. Dossumbekova, B. Neu // Gut. – 2004. – Vol. 53. – P. 1082-1089.

468.Relationship between gastric mucosal IL-8 levels and histological gastritis in patients with Helicobaсter pylori infection / J. Xuan, R. Deguchi, H. Yanagi et al. // Tokai J. Exp. Clin. Med. – 2005. – Vol. 30, № 2. – Р. 83-88.

469.Relationship between onset of peptic ulcer and meteorological factor / Liu DaYun, Gao An-Ning, Tang Guo-Du et al. // World J. Gastroenterol. – 2006. – Vol. 12, № 9. – P. 1463-1467.

470.Relationship between pepsinogen I & II and H. pylori infection considered with grade of atrophy and gastroduodenal diseases / М. Karita, А. Noriyasu, Е. Kosako et al. // Dig. Dis. Sci. – 2003. – № 48. – Р. 1839-1845.

471.Repot Card to Grade Helicobacter pylori / D. Y. Graham, L. U. Hong, Y. A. Yamaoka et al. // Therapy. Helicobacter. – 2007. – № 12. – P. 275 – 278.

472.Resistance rate to antibiotics of Helicobacter pylori isolates in easterm Taiwan / C. T. Hu, C. C. Wu, C. Y. Lin et al. // J. Gastroenterol. Hepatol. – 2007. – Vol. 22, № 7. – P. 720-723.

187

473.Results from the Pediatric European Register for treatment of Helicobacter pylori (PERTH) / G. Oderda, P. Shcherbakov, P. Bontems et al. // Helicobacter. – 2007. – Vol.

12.– P. 150-156.

474.Risk factors for arterial hypertension and ischemic heart disease in workers from carbamide production / M. Koleva, T. Kuneva, E. Arabadzhiyska еt al. // Scr. Sci. med. – 1997. – Vol. 29, № 3. – P. 119-123.

475.Risk factors forpeptic ulcer disease : A population based cohort study comprising 2415 Danish adults / S. Rosenstock, T. Jorgensen, O. Bonnevie et al. // Gut. – 2003.

– Vol. 52. – P. 186-193.

476.Romagnani, S. Th1 and Th2 in human diseases / S. Romagnani // Clin. Immunol. Immunopathol. – 1996. – № 80. – Р. 225-235.

477.Rugge, M. Staging gastritis: an international proposal / M. Rugge, R. M. Genta // Gastroenterology. – 2005. – Vol. 129, № 5. – Р. 1807-1808.

478.Safety of the long-term use of proton pump inhibitors / A. B. Thomson, M. D. Sauve, N. Kassen et al. // World J. Gastroenterol. – 2010. – Vol. 16, № 19. – Р. 2323-30.

479.Serum levels of amidated gastrin-17 and pepsinogen- I in atrophic gastritis. An observational case-control study / Р. Sipponen, P. Ranta, Т. Helske et al. // Scand G. Gastroenterol. – 2002. – № 37. – Р. 785-791.

480.Severe reflux disease is associated with an enlarged unbuffered proximal gastric acid pocket / A. T. Clarke, A. A. Wirz, J. J. Manning et al. // Gut. – 2008. – Vol. 57. – P. 292-297.

481.Slomiany, B. L. Role of interleukin-4 in down-regulation endothelin-1 during gastric ulcer healing: effect of sucralfate / B. L. Slomiany, J. Piotrowski, А. Slomiany // Physiol-Pharmacol. – 2000. – Vol. 51, № 1. – P. 69-83.

482.Sluieter, J. Criteria document for evaluating the work-relatedness of upperextremity musculoskeletal disorders / J. Sluieter, K. M. Rest, M. H. W. Frings-Dresen // Scand. J. Work Environ Health. – 2001. – Vol. 27, Suppl. 1. – 102 p.

483.Smith, A. G. P. Cytokine and cytokine receptor polymorphism and functionality / A. G. P. Smith, S. E. Humphries // Cytokine Growth Factor Rev. – 2008. – Vol. 516.

– P. 17-34.

484.Sung, J. J. Marshall and Warren Lecture 2009: Peptic Ulcer Bleeding: An expedition of 20 years from 1989-2009 / J. J. Sung // J. Gastroenerol. Hepatol. – 2010. – Vol. 25, №. 2. – P. 229-233.

485.Sung, J. J. Systematic review: the global incidence and prevalence of peptic ulcer disease / J. J. Sung, E. J. Kuipers, H. B. El-Serag // Aliment. Pharmacol. Tber. – 2009.

– № 29. – Р. 938-46.

486.Than, A. Diminished Th-1 type cytokine production in gastric mucosa T- lymphocytes after H. pylory eradication in duodenal ulcer patients / А. Than, В. Tepes, М. Gubina // Pflugers Arch. – 2000. – Vol. 440, № 5, suppl. – Р. R89-R90.

487.The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment. Pharmacol / А. Kokkola, Р. Sipponen, Н. Rautelin et al. // Ther. – 2002. – № 16. – Р. 515-520.

488.The еfficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis / P. Lin, C. Chang, P. Hsu et al. // Crit. Care Med. – 2010. – Vol. 38, № 4. – Р. 1197-1205.

489.The laboratol metods researches imcondition of immunity / M. Digeon, M. Laver, J. Riza et al. // J. Immunol. Methods. – 1977. – №. 16. – P. 165-183.

188

490.The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis / В. Annibale, Е. Di Glulio, Р. Caruana еt al. // Aliment. Pharmacol. Ther. – 2002. – № 16. – Р. 1723-1731.

491.The polymorphic IL-1b and IL-1RN genes in the aetiopathogenesis of peptic ulcer / М. А. Garcia-Gonzales, А. Lanas, S. Santolaria et al. // J. Clin-Exp-Immunol. – 2001. – Vol. 125, № 3. – Р. 368-375.

492.The polymorphism IL-8-251 A/T influences the susceptibility of Helicobaсter pylori related gastric diseases in the Japanese population / M. Olyauchi, A. Imatani, M. Yonechi et al // Gut. – 2005. – Vol. 54, № 3. – Р. 330-335.

493.Thomson, A. B. R. ReQuest: pain, pH, pills and promises / A. B. R. Thomson

//J. Clin. Gastroenterology. – 2007. – Vol. 41, (suppl. 2). – P. 81-86.

494.Total eguivalent of reactive chemicals in 149 human food items is highly variable within and between major food groups / N. He, K. Openo, M. Mc. Cullought et al // G. Nutr. – 2004. – Vol. 34. – P. 1114-1119.

495.Treatment of Helicobacter pylori infection / A. O'Connor, J. Gisbert, C. O'Morain et al. // Helicobacter. – 2009. – Vol. 14, Suppl. 1. – P. 46-51.

496.Vdovychenko, V. Dynamics of Helicobacter pylori strains resistance to antibiotics and prognosis of the effectiveness of pеptic ulcer treatment of IVIV province residents / V. Vdovychenco, A. Demydova // Abstracts of 15-th European Gastroenterology week. – 2007. – OP-G-152.

497.Veldhuyzen van Zanten, S. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview / S. Veldhuyzen van Zanten, P. Sherman // Can. Med. Assoc. J. – 2001. – P. 177-182.

498.WHO. Global strategy on occupational health for all. The way to health at work // WHO/OCH/95.1. – Geneva, 1995. – 68 p.

499.WHO EUROPE. Good practice in occupaitional health services:a contribution to workplace health. EUR/ 02/5041181. – Copenhagen: WHO ROE, 2002.

500.Yamaoka, Y. Geographic differences in gastric incidence can be explained by difference between Helicobacter pylori strains / Y. Yamaoka, M. Kato, M. Asaka // Inter. Med. – 2008. – Vol. 47. – P. 1077-1083.

501.Zhou, L. Y. The changes of gastric diseases during the past twenty five years / L. Y. Zhou, Y. Xue, S. R. Lin et al. // Zhonghua Nei. Ke. Za. Zhi. – 2005. – Vol. 44, №. 6. – P. 431-433.

502.Zullo, A. How harmful is the presence of intestinal metaplasia in the stomach? / A. Zullo, C. Hassan // Gastroenterology. – 2009. – Vol. 136, № 4. – Р. 1461-1462.

Монография

Помыткина Татьяна Евгеньевна

ОСОБЕННОСТИ ТЕЧЕНИЯ ЯЗВЕННОЙ

БОЛЕЗНИ У РАБОТНИКОВ ПРОИЗВОДСТВА

СОЕДИНЕНИЙ АЗОТНОЙ ГРУППЫ

(клинико-гигиеническое исследование)

Подписано в печать 28.11.2013 г. Тираж 525 экз. Формат 21×30½. Условных печатных листов 11.

Отпечатано с готового авторского макета ГБОУ ВПО КемГМА Минздравсоцразвития России

650029, Кемерово, ул. Ворошилова, 22а.